Tildrakizumab for Psoriasis Shows Durable Efficacy Over 5 Years Tildrakizumab for Psoriasis Shows Durable Efficacy Over 5 Years

The full 5-year results of a study of tildrakizumab for psoriasis show a high rate of sustained disease control coupled with a favorable safety profile during more than 5400 patient-years of follow-up.Medscape Medical News

Source: Medscape Dermatology Headlines - November 21, 2020 Category: Dermatology Tags: Dermatology News Source Type: news